DK2388315T3 - Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling - Google Patents

Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Info

Publication number
DK2388315T3
DK2388315T3 DK11174887.7T DK11174887T DK2388315T3 DK 2388315 T3 DK2388315 T3 DK 2388315T3 DK 11174887 T DK11174887 T DK 11174887T DK 2388315 T3 DK2388315 T3 DK 2388315T3
Authority
DK
Denmark
Prior art keywords
therapeutic treatment
myxoma virus
express functional
express
functional
Prior art date
Application number
DK11174887.7T
Other languages
Danish (da)
English (en)
Inventor
John Barrett
Marianne Stanford
Grant Mcfadden
Original Assignee
Univ Western Ontario
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Ontario filed Critical Univ Western Ontario
Application granted granted Critical
Publication of DK2388315T3 publication Critical patent/DK2388315T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK11174887.7T 2005-03-07 2006-03-06 Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling DK2388315T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
EP06705269A EP1863906A4 (en) 2005-03-07 2006-03-06 COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN USED IN THERAPEUTIC TREATMENT

Publications (1)

Publication Number Publication Date
DK2388315T3 true DK2388315T3 (da) 2014-08-25

Family

ID=36952904

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11174887.7T DK2388315T3 (da) 2005-03-07 2006-03-06 Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Country Status (14)

Country Link
US (5) US20090035276A1 (cg-RX-API-DMAC10.html)
EP (2) EP2388315B1 (cg-RX-API-DMAC10.html)
JP (2) JP2008531739A (cg-RX-API-DMAC10.html)
KR (1) KR101479093B1 (cg-RX-API-DMAC10.html)
CN (2) CN101137748B (cg-RX-API-DMAC10.html)
AU (1) AU2006222500B2 (cg-RX-API-DMAC10.html)
CA (1) CA2600675C (cg-RX-API-DMAC10.html)
DK (1) DK2388315T3 (cg-RX-API-DMAC10.html)
IL (2) IL185376A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007010962A (cg-RX-API-DMAC10.html)
NZ (2) NZ577283A (cg-RX-API-DMAC10.html)
RU (1) RU2461630C2 (cg-RX-API-DMAC10.html)
UA (1) UA96412C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006094385A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
US8512713B2 (en) * 2006-06-01 2013-08-20 Robarts Research Institute Myxoma virus mutants for cancer treatment
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
EP2717887B1 (en) * 2011-06-09 2017-12-27 University of Florida Research Foundation, Inc. Methods for treating or preventing graft versus host disease
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
WO2020033510A1 (en) * 2018-08-08 2020-02-13 Arizona Board Of Regents On Behalf Of Arizona State University Method for improved poxvirus yields
CA3112788A1 (en) 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
CA3152787A1 (en) 2019-09-02 2021-03-11 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
CN114828861A (zh) * 2019-10-10 2022-07-29 亚利桑那州立大学董事会 表达多特异性免疫细胞接合器的溶瘤病毒
US20240091284A1 (en) * 2019-10-10 2024-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP1314430A1 (en) 1996-01-25 2003-05-28 The University Court Of The University Of Glasgow Treatment of non-neuronal cancer using HSV mutant
EP1003894A2 (en) 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
AU6175000A (en) 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
BR0015491A (pt) * 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
WO2001087324A1 (en) * 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2004014314A2 (en) * 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
WO2004078206A1 (en) * 2003-03-07 2004-09-16 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
DK2388315T3 (da) 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling

Also Published As

Publication number Publication date
IL185376A0 (en) 2008-02-09
NZ577283A (en) 2010-11-26
WO2006094385A1 (en) 2006-09-14
AU2006222500A1 (en) 2006-09-14
HK1163175A1 (en) 2012-09-07
NZ560840A (en) 2009-07-31
EP2388315A3 (en) 2012-05-02
US20180256656A1 (en) 2018-09-13
EP2388315B1 (en) 2014-05-21
AU2006222500B2 (en) 2011-09-01
RU2461630C2 (ru) 2012-09-20
IL208070A0 (en) 2010-12-30
JP2008531739A (ja) 2008-08-14
MX2007010962A (es) 2008-03-10
EP2388315A2 (en) 2011-11-23
CA2600675C (en) 2015-12-15
RU2007137008A (ru) 2009-04-20
US20140134134A1 (en) 2014-05-15
US20130171106A1 (en) 2013-07-04
CN101137748B (zh) 2011-12-14
KR101479093B1 (ko) 2015-01-26
CN102357104B (zh) 2016-01-27
EP1863906A1 (en) 2007-12-12
US20110195050A1 (en) 2011-08-11
UA96412C2 (ru) 2011-11-10
EP1863906A4 (en) 2009-06-03
CN102357104A (zh) 2012-02-22
CN101137748A (zh) 2008-03-05
IL208070A (en) 2015-06-30
JP2012236860A (ja) 2012-12-06
US20090035276A1 (en) 2009-02-05
JP5674210B2 (ja) 2015-02-25
US9987315B2 (en) 2018-06-05
CA2600675A1 (en) 2006-09-14
KR20070110423A (ko) 2007-11-16

Similar Documents

Publication Publication Date Title
DK2311464T3 (da) Midler til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne
DK2187878T3 (da) Anvendelse af en betablokker til fremstilling af et medikament til behandling af hæmangiomer
EP1885414A4 (en) DEVICE FOR MEDICAMENT ADMINISTRATION
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
ES2352576T8 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana.
CR10508A (es) Nuevo determinante de virulencia dentro de la glicoproteina estructural e2 del virus de la peste porcina clasica
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
DK2058020T3 (da) Indretning til indgivelse af lægemiddel
DK2220076T5 (da) Inhibitorer af replikationen af humant immundefektvirus
DK1833532T3 (da) Sikkerhedssprøjte
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
PL2281831T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
DK1827441T3 (da) Kombinationer til behandling af sygdomme, som involverer celleproliferation
PL3424932T3 (pl) Boronoftalidy do zastosowania terapeutycznego
DK2148670T3 (da) Titrering af tapentadol
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
BRPI0912285A2 (pt) anticorpos monoclonais tendo propriedades de neutralização cruzada de homosubtipo contra o vírus influenza subtipo h1.
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
BRPI0913216A2 (pt) uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus.
BRPI0808246A2 (pt) "fralda descartável".
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
BRPI0819992A2 (pt) Métodos para operar um dispositivo médico e para habilitar numerosos aspectos operacionais de um dispositivo médico, e, dispositivo médico
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
DE602006013636D1 (de) Dosiszähler